Refine
Has Fulltext
- yes (69)
Is part of the Bibliography
- yes (69)
Year of publication
Document Type
- Journal article (60)
- Preprint (6)
- Conference Proceeding (3)
Language
- English (69)
Keywords
- PET (17)
- Positronen-Emissions-Tomografie (16)
- prostate cancer (13)
- theranostics (11)
- positron emission tomography (10)
- PSMA (7)
- neuroendocrine tumor (7)
- radioligand therapy (7)
- CXCR4 (6)
- PET/CT (6)
- PRRT (6)
- SPECT (6)
- SSTR (5)
- prostate-specific membrane antigen (5)
- PSMA-RADS (4)
- RADS (4)
- molecular imaging (4)
- sympathetic nervous system (4)
- 18F-DCFPyL (3)
- DaTscan (3)
- NET (3)
- Prostate Cancer (3)
- ageing (3)
- machine learning (3)
- norepinephrine transporter (3)
- peptide receptor radionuclide therapy (3)
- reporting and data system (3)
- somatostatin receptor (3)
- 11C-HED (2)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 18F-LMI1195 (2)
- C-X-C motif chemokine receptor 4 (2)
- DOTATOC (2)
- Ioflupane (2)
- MAG3 (2)
- MRI (2)
- PSMA I&T (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- SSTR-RADS (2)
- SUV (2)
- Stammzelle (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- [68Ga]PentixaFor (2)
- cardiac innervation imaging (2)
- cardiac nerve (2)
- cardiomyocytes (2)
- chemokine receptor (2)
- diabetes (2)
- endoradiotherapy (2)
- fatty acid (2)
- heart failure (2)
- hiPSC-CM (2)
- induced pluripotent stem cells (2)
- inflammation (2)
- kidney (2)
- molecular medicine (2)
- multiple myeloma (2)
- myocardial sympathetic innervation imaging (2)
- personalized medicine (2)
- precision medicine (2)
- prostate-specific membrane antigen (PSMA) (2)
- somatostatin receptor (SSTR) (2)
- stem cell therapy (2)
- tracer (2)
- tumor heterogeneity (2)
- 11C-Hydroxyephedrine (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 177Lu (1)
- 18F-DCFPL (1)
- 18F-FDG (1)
- 18F-FDS (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- Antidepressants (1)
- Arginine (1)
- COVID-19 (1)
- CTCAE (1)
- CXCR4-targeting (1)
- Cardiovascular diseases (1)
- DCGAN (1)
- ECG (1)
- FV45 (1)
- GAN (1)
- GCA (1)
- Ganglia (1)
- Gleason score (1)
- HFmrEF (1)
- Heart failure (1)
- Hyperkalaemia (1)
- ICD (1)
- Imaging pitfalls (1)
- Journal of Nuclear Cardiology (1)
- Lysine (1)
- MDD (1)
- MI-RADS (1)
- MIBG (1)
- MPI (1)
- Magnetresonanztomografie (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- PMR (1)
- PROMISE (1)
- PSA (1)
- PSA response (1)
- PSMA-617 (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-TV (1)
- PSMA-targeted PET (1)
- PSMA‐617 (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- Pitfall (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Prostata (1)
- RLT (1)
- Radiofluorine (1)
- Radiotracer (1)
- SARS-CoV-2 (1)
- SPECT Scanner (1)
- SPECT/CT (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- TKI (1)
- Tracer (1)
- ZDF rats (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{177}\)Lu (1)
- \(^{18}\)F (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- adrenocortical carcinoma (1)
- amino acids (1)
- angiogenesis (1)
- angiotensin II type 1 receptor (1)
- antidepressant (1)
- arrhythmia (1)
- artificial intelligence (1)
- biomarkers (1)
- blood flow (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardioprotective potential (1)
- combination (1)
- computational biology and bioinformatics (1)
- coronary artery disease (1)
- depression (1)
- diabetic cardiomyopathy (1)
- editorial (1)
- ejection fraction (1)
- endocrinology (1)
- fibroblast activation protein (1)
- flare phenomenon (1)
- focused surgical approach (1)
- giant cell arteritis (1)
- glomerular filtration rate (1)
- heart failure with mid-range ejection fraction (1)
- hematotoxicity (1)
- hydroxyephedrine (1)
- hyperkalemia (1)
- immune infiltration (1)
- interobserver (1)
- interreader (1)
- kidney function (1)
- late response (1)
- left-ventricular function (1)
- mRNA (1)
- magnetic resonance imaging (1)
- major depressive disorder (1)
- matched pair (1)
- medicine (1)
- medium-sized animals (1)
- medullary thyroid carcinoma (1)
- meningioma (1)
- miRNA (1)
- moycardial sympathetic innervation (1)
- myocardial nerve (1)
- myocardial perfusion imaging (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasia (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumors (NET) (1)
- neurology (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- overall survival (1)
- pancreas (1)
- papillary thyroid carcinoma (PTC) (1)
- parathyroid adenoma (1)
- performance (1)
- personalized treatment (1)
- phaeochromocytoma (1)
- polymyalgia rheumatica (1)
- prediction (1)
- primary hyperparathyroidism (1)
- prostate-specific antigen (1)
- radioiodine (1)
- radiotracer (1)
- radiotracer kinetics (1)
- rats (1)
- renal (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- renin-angiotensin system (1)
- reporting and data systems (1)
- sarcoidosis (1)
- selpercatinib (1)
- sigma-1 receptor-directed molecular imaging (1)
- single photon emission computed tomography: sympathetic nerve (1)
- solid tumors (1)
- split renal function (1)
- staging (1)
- standardization (1)
- standardized reporting (1)
- standardized reporting system (1)
- statin (1)
- stem cells (1)
- stem-cell research (1)
- storage vesicle turnover (1)
- stroke (1)
- structure–activity relationships (1)
- taxane (1)
- thyroid carcinoma (TC) (1)
- transcriptome (1)
- tumor microenvironment (1)
- tyrosine kinase inhibitor (1)
- urology (1)
- valsartan (1)
- vandetanib (1)
- vasculature (1)
- vasculitis (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (69)
- Medizinische Klinik und Poliklinik II (10)
- Medizinische Klinik und Poliklinik I (9)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (8)
- Urologische Klinik und Poliklinik (8)
- Institut für Pharmazie und Lebensmittelchemie (4)
- Comprehensive Cancer Center Mainfranken (3)
- Pathologisches Institut (3)
- Institut für Anatomie und Zellbiologie (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Center for Computational and Theoretical Biology (1)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (1)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (1)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (15)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Johns Hopkins University School of Medicine (2)
- Department of Nuclear Medicine, Kanazawa University (1)
- Johns Hopkins Medicine (1)
- Johns Hopkins School of Medicine, Baltimore, MD, USA (1)
- Johns Hopkins University, Baltimore, MD, U.S. (1)
EU-Project number / Contract (GA) number
- 701983 (28)
Background
Peptide receptor radionuclide therapy (PRRT) is applied in patients with advanced neuroendocrine tumors. Co-infused amino acids (AA) should prevent nephrotoxicity. The aims of this study were to correlate the incidence of AA-induced hyperkalemia (HK) (≥5.0 mmol/l) and to identify predictors of AA-induced severe HK (>6.0).
Methods
In 38 patients, standard activity of \(^{177}Lu\)-labelled somatostatin analogs was administered. Pre-therapeutic kidney function was assessed by renal scintigraphy and laboratory tests. For kidney protection, AA was co-infused. Biochemical parameters (potassium, glomerular filtration rate, creatinine, blood urea nitrogen (BUN), sodium, phosphate, chloride, and lactate dehydrogenase (LDH)) were obtained prior to 4 and 24 h after the AA infusion. Incidence of HK (≥5.0) was correlated with pre-therapeutic kidney function and serum parameters. Formulas for the prediction of severe hyperkalemia (>6.0) were computed and prospectively validated.
Results
At 4 h, HK (≥5.0) was present in 94.7% with severe HK (>6.0) in 36.1%. Values normalized after 24 h in 84.2%. Pre-therapeutic kidney function did not correlate with the incidence of severe HK.
Increases in K+ were significantly correlated with decreases in phosphate (r = −0.444, p < 0.005) and increases in BUN (r = 0.313, p = 0.056). A baseline BUN of >28 mg/dl had a sensitivity of 84.6% and a specificity of 60.0% (AUC = 0.75) in predicting severe HK of >6.0 (phosphate, AUC = 0.37).
Computing of five standard serum parameters (potassium, BUN, sodium, phosphate, LDH) resulted in a sensitivity of 88.9% and a specificity of 79.3% for the prediction of severe HK >6.0 (accuracy = 81.6%).
Conclusions
A combination of serum parameters predicted prospectively the occurrence of relevant HK with an accuracy of 81.6% underlining its potential utility for identifying ‘high-risk’ patients prone to PRRT.